STUDY ON THE MONITORING OF INFLAMMATORY MARKERS IN SARS- COV2 INFECTION
TATIANA CIUREA 1, DANIELA TIŢĂ 2, MARIA PRISECARU 3, IONUŢ STOICA 3, DIANA IOANA TIŢĂ 4 1. Bagdasar-Arseni Emergency Clinical Hospital, Bucharest, e-mail: ciurea_t@yahoo.com
2. Bacau Emergency County Hospital, Romania; e-mail: danielatita2007@yahoo.com
3. „Vasile Alecsandri” University of Bacau, Faculty of Science, Department of Biology, Bacau, Romania, e-mail: prisecaru_maria@yahoo.com; ionut_stoica23@yahoo.com
4. University Dunarea de Jos Galati, Faculty of Medicine and Pharmacy, e-mail: dianaioana2525@yahoo.com.
COVID-19 may present as a silent asymptomatic infection, a mild upper respiratory tract disease or a severe illness characterized by fulminant inflammation, systemic coagulopathy and severe damage to the lungs and cardiovascular system and other organs. Acute respiratory distress syndrome (ARDS) and multiple organ dysfunctions are among the leading causes of death and severe forms in patients diagnosed with CoV-19. Severely ill patients (CoV-19) have hyper inflammation and associated biomarkers provide useful information for risk assessment. Moreover, the serum levels of inflammatory markers such as: Il-6, ferritin, CRP, D-dimers are closely related to the severity of the disease.
